GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

Have you ever pondered over the ingredients list on your toothpaste tube and wondered what those scientific names mean, let ...

Med spas together with hospital systems have started compressing private practices; Dr. Meegan Gruber urges patients to ...

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life ...

Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Black Book's 18-country survey reveals 74% of health systems advancing large-scale rollouts by 2027, fueled by ...

DOUGLAS Group achieves solid growth and confirms guidance for 2024/25 Solid Q3 sales growth across all segments except France: Group sales increased by 3.2%, or 4.0% excluding the sold-off online ...

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose ...

Recently Announced Strategic Acquisition of SiVantage Portfolio Energizes Tenon's Commercial Organization and Accelerates Topline Growth ~~ FDA Clearance Unlocks New Sacro-Pelvic Market Opportunity ...

SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ...

Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-- Raised $8.8 million in gross proceeds from a private placement and ...